telmesteine
3,4-thiazolidinedicarboxylic acid, 3-ethyl ester, (R)-
Identification
| Name | telmesteine |
| IUPAC | (4R)-3-ethoxycarbonyl-1,3-thiazolidine-4-carboxylic acid |
| CAS Number | 122946-43-4 |
| FDA UNII | 124I3FE35T |
| Molecular Formula | C7 H11 N O4 S |
| Molecular Weight | 205.23347000 |
| MDL Number | MFCD00867667 |
| Nikkaji Number | J561.874F |
| XlogP3 | 0.60 (est) |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Soluble in | water, 9.987e+004 mg/L @ 25 °C (est) |
Cosmetic Information
| CosIng | cosmetic data |
| Cosmetic Uses | antioxidants |
No sensory data available
Safety Information
| Oral/Parenteral Toxicity | Not determined |
| Dermal Toxicity | Not determined |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | antioxidants |
| Recommendation for telmesteine usage levels up to | not for fragrance use. |
| Recommendation for telmesteine flavor usage levels up to | not for flavor use. |
BOC Sciences
Best of Chemicals Supplier
Quality supplier of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecul...
Potential Uses
Natural Occurrence
Synonyms
(4R)-3-
ethoxycarbonyl-1,3-thiazolidine-4-carboxylic acid
3,4-
thiazolidinedicarboxylic acid, 3-ethyl ester, (R)-
PubMed:
Treatment of pruritus in mild-to-moderate atopic dermatitis with a topical non-steroidal agent.
PubMed:
A double-blind, randomised, vehicle-controlled clinical study to evaluate the efficacy of MAS065D in limiting the effects of radiation on the skin: interim analysis.
PubMed:
Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial.
PubMed:
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
PubMed:
A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (XClair), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis.
PubMed:
Steroids versus other immune modulators in the management of allergic dermatoses.
PubMed:
A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults.
PubMed:
A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis.
PubMed:
Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat.
PubMed:
[Telemestein and variations in blood concentrations of lipoprotein A].